GlassScriptPhysician profile
Michael Akpeke
NPI 1386722403
$6,214.70
in general payments reported to CMS, 2019-2025
40 companies · $934 in 2025
The $934 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $685 · 2021: $887 · 2022: $926 · 2023: $1,219 · 2024: $958 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,110.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,485.47 | 2019-2025 | Breztri, Airsupra, Tagrisso |
| Bayer Healthcare Pharmaceuticals INC. | $661.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $653.97 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Lilly USA, LLC | $569.03 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $299.48 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $240.92 | 2019-2022 | |
| Pfizer INC. | $210.52 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $194.17 | 2019-2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.66 | 2019-2025 | Xifaxan |
| Evoke Pharma, INC. | $143.74 | 2025 | |
| Esperion Therapeutics, INC. | $142.88 | 2020-2025 | Nexletol |
| Gilead Sciences, INC. | $120.53 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $119.50 | 2025 | |
| Genzyme Corporation | $113.85 | 2024 | |
| Allergan, INC. | $112.15 | 2019-2020 |
Show all 37 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Akpeke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.